Paragon 28, Inc. Provides Revenue Guidance for the First Quarter and Full Year of 2021
March 08, 2022 at 04:01 pm EST
Share
Paragon 28, Inc. provided revenue guidance for the first quarter and full year of 2021. For the first quarter of 2022, the company expects net revenue growth to be in a range of 13% to 16%, compared to the first quarter of 2021.
The company expects 2022 net revenue to be in a range of $167.0 million to $171.0 million, representing annual growth of approximately 13% to 16%.
Paragon 28, Inc. is a medical device company focused on the foot and ankle orthopedic market. The Company provides orthopedic solutions, procedural approaches and instrumentation that cover a range of foot and ankle ailments, including fracture fixation, forefoot, ankle, progressive collapsing foot deformity (PCFD) or flatfoot, Charcot foot and orthobiologics. To treat these painful, debilitating or even life-threatening conditions, it provides a portfolio of solutions that includes surgical implants and disposables, as well as surgical instrumentation. Its broad suite of surgical solutions comprises nearly 80 product systems to help fit the specific needs of each patient and procedure. It has developed a comprehensive portfolio of foot and ankle surgical systems. Each system typically includes plates, screws, staples, nails, advanced joint and bone replacements, orthobiologics, and other implantation instruments and disposables specifically designed for the particular surgical system.